News | Cardiac Diagnostics | August 27, 2018

Acarix Presents CADScor System at ESC 2018

Non-invasive, radiation-free device delivers high-sensitivity and -specificity assessment of coronary artery disease risk in less than 10 minutes

Acarix Presents CADScor System at ESC 2018

August 27, 2018 — Acarix AB’s ultra-sensitive acoustic CADScor System for coronary artery disease risk assessment will be on display at the European Society of Cardiology (ESC) Congress 2018, Aug. 25-28 in Munich, Germany. The CADScor System has been validated clinically to rule out CAD with 96-97 percent negative predictive value. The device is gaining interest and increased use across Germany and Denmark, key Swedish hospitals are testing the system and expansion in other European countries is under way. At ESC 2018, both in the exhibition booth and at a special session Aug. 28, there will be opportunities to get first-hand information about the CADScor System and to meet experts with experience from using the system in clinical practice.

The low diagnostic yield of current non-invasive testing in patients with suspected coronary artery disease has recently been described by Christina Therming et al.1 for a large hospital-based sample. Acarix CADScor System has been developed to add a reliable and simple diagnostic aid to the non-invasive diagnostic landscape that is easy to handle as a first line test in each clinical setting. The system is noninvasive, radiation-free and delivers a result in less than 10 minutes.

At ESC, visitors will hear how the performance of the CADScor System has recently been further documented. The system’s Algorithm v3 database contains 2,260 patients and performs with a sensitivity of 88.7 percent, specificity of 53.5 percent and a negative predictive value (NPV) of 95.9 percent for diagnosing CAD (stenosis >50 percent) versus non-CAD (stenosis < 30 percent). The NPV is 97.2 percent for diagnosing CAD (stenosis >50 percent) versus non-obstructive CAD (stenosis >30-< 50 percent) plus non-CAD (stenosis < 30 percent) (publication in preparation). Furthermore, a new study, Dan-NICAD II, is ongoing involving 1,500-2,000 patients with a low-to-intermediate likelihood of CAD from four Danish hospitals. The results are expected to further improve the CADScor System‘s already high NPV, to include patients aged < 40 years and to provide health economic documentation supporting its use as a fast and safe frontline assessment to reduce patient referrals.

For more information: www.acarix.com

Reference

1. Therming C., Galatius S., Heitmann M., et al. Low diagnostic yield of non-invasive testing in patients with suspected coronary artery disease: results from a large unselected hospital-based sample. European Heart Journal - Quality of Care and Clinical Outcomes, Dec. 18, 2017. https://doi.org/10.1093/ehjqcco/qcx048


Related Content

News | Cardiac Diagnostics

September 15, 2022 - Happitech has announced the launch of its FastStart Research app. The Amsterdam-based digital ...

Home September 15, 2022
Home
Feature | Cardiac Diagnostics | by Kelly Patrick

Like most healthcare markets, the diagnostic cardiology market has had a bumpy ride in recent years. The COVID-19 ...

Home August 23, 2022
Home
Feature | Cardiac Diagnostics | By Adam Saltman, MD, PhD

Before opining on the future of cardiac health, I think it’s important to define what “cardiac health” actually is. If ...

Home May 04, 2022
Home
News | Cardiac Diagnostics

January 31, 2022 — Scientists have developed an artificial intelligence (AI) system that can analyze eye scans taken ...

Home January 31, 2022
Home
News | Cardiac Diagnostics

November 10, 2021 — Abbott released new global market research from its Beyond Intervention initiative, the company’s ...

Home November 10, 2021
Home
Feature | Cardiac Diagnostics | By Dave Fornell, DAIC Editor

October 29, 2021 — A new guideline for the evaluation and diagnosis of chest pain was released this week that provides ...

Home October 29, 2021
Home
News | Cardiac Diagnostics

October 4, 2021 – Nanowear, a hospital-at-home and remote diagnostic platform that used proprietary wearable cloth ...

Home October 04, 2021
Home
News | Cardiac Diagnostics

September 28, 2021 — Biotricity Inc., a medical diagnostic and consumer healthcare technology company, has developed a ...

Home September 28, 2021
Home
News | Cardiac Diagnostics

July 29, 2021 — A recent clinical study from Overlake Medical Center utilizing the Bardy Diagnostics Carnation ...

Home July 29, 2021
Home
News | Cardiac Diagnostics

July 1, 2021 — The U.S. Food and Drug Administration (FDA) has cleared the Angel Medical Systems Inc. second-generation ...

Home July 01, 2021
Home
Subscribe Now